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Abstract
Cervical cancer is the fourth most common cancer in women worldwide and mainly affects younger women. The
mortality associated with cervical cancer can be reduced if this disease is detected at the pre-cancer stage. Current
gold standard methods include cytopathology, HPV testing and histopathology but these methods are limited in
terms of subjectivity, cost and time. There is an unmet clinical need for new methods to aid clinicians in the early
detection of cervical pre-cancer. These methods should be objective, rapid and require minimal sample preparation.
Raman spectroscopy is a vibrational spectroscopic technique by which incident radiation is used to induce vibrations
in the molecules of a sample and the scattered radiation may be used to characterise the sample in a rapid and nondestructive manner. Raman spectroscopy is sensitive to subtle biochemical changes occurring at the molecular level
allowing spectral variations corresponding to disease onset to be detected. Over the past 15 years, there have been
numerous reports showing the potential of Raman spectroscopy together with multivariate statistical analysis for the
detection of a variety of cancers. This paper discusses the recent advances and issues for cervical cancer screening
and diagnosis and offers some perspectives for the future.

Keywords
Raman spectroscopy, cervical cancer, cervical intraepithelial neoplasia (CIN), low grade squamous intraepithelial
lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), cytopathology, histopathology, human papilloma
virus (HPV)
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1.

Cervical cancer

Cervical cancer is the fourth most common cancer in women worldwide, accounting for an estimated 528,000 new
cases and 266,000 deaths in 2012 [1]. The mortality associated with cervical cancer can be reduced if this disease is
detected at the early stages of development or at the pre-malignant stage (cervical intraepithelial neoplasia, CIN).
Unlike most other types of cancer, cervical cancer affects mainly younger women, with about 60% of cases
occurring in women under 50 years of age. Persistent infection with high risk human papillomavirus (HPV) (e.g.,
HPV types 16, 18) is accepted as the major cause for the development of cervical pre-cancer and cancer [2]. Other
risk factors include smoking, immunosuppression, long term use of oral contraceptives and socioeconomic status [3].
Cervical cancer begins in the basal layer of cells lining the cervix when the normal cells slowly change into precancer cells that have the potential to turn into cancer. The gradual progression of cervical cancer can allow the
detection of dysplastic changes before invasive cancer develops, through cervical cancer screening programmes.
These screening programmes are common in developed countries, greatly reducing the mortality rates due to cervical
cancer, but are not yet implemented in developing countries due to lack of infrastructure and funding.

2.

Cervical cancer screening and diagnosis

2.1 The Pap test
The Pap test, also called the Pap smear, cervical smear or smear test, is a screening method invented independently
by Georgios Papanicolau and Aurel Babeş, but named after Papanicolau. It was introduced in the mid 1940s and
currently it is the most common screening method for cervical neoplasia and its precursor lesions [4].
The smear is collected by scraping the internal wall of the cervix with a cervical brush to obtain representative
material from the transformation zone where the stratified squamous epithelium of the ectocervix turns into the
columnar mucus secreting epithelium of the endocervix. The cells are then transferred onto a microscope slide by
either the conventional method, in which the cells are spread along the slide immediately after collection and fixed
with a spray fixative, or by liquid based cytology (LBC), in which the cells are transferred immediately after
collection into a vial with a fixative solution and subsequently processed to remove debris and transferred to a slide
(ThinPrep® (Hologic) or SurePath® (BD)).
Once on a slide, the cells are Pap stained and evaluated under the microscope by a highly trained cytotechnologist or
a pathologist according to the Bethesda system [5].
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Cervical cytology is normally graded as negative (negative for intraepithelial lesion or malignancy [NILM]), low
grade squamous intraepithelial lesion [LSIL] and high grade squamous intraepithelial lesion [HSIL]. LSIL may
regress but HSIL is unlikely to do so and may progress to invasive disease. Current guidelines are that LSIL cases
are re-tested after 6 months and HSIL cases are referred to colposcopy [6].

A normal Pap stained cervical smear, such as that shown in figure 1, typically shows cells from the surface of the
epithelium; intermediate cells, which are large polygonal cells with a round to oval nucleus and a blue stained
cytoplasm, and superficial cells, which are large polygonal cells with a small condensed nucleus and a pink to orange
stained cytoplasm. Parabasal cells, which are small round or oval cells with the nucleus occupying half of the cell
and a dense blue stained cytoplasm, can also be found, but these are more prominent in smears from postmenopausal
women. Metaplastic cells, endocervical cells and endometrial cells can also all be present in a normal smear. The
most common non-epithelial cells present in the normal smear are white blood cells, including polymorphs
(neutrophils) or macrophages (histiocytes), which can increase in number due to infection and inflammation.

The advantages of the Pap test are that it is non-invasive, inexpensive and widely accepted. However, although it can
have high specificity of up to 95-98%, sensitivity rates have been shown to vary from 74 to 96% due to sampling,
technical and/or interobserver errors mainly associated with the subjectivity of the cytological screening [7].

Semi-automated screening systems consist of an automated microscope coupled to a workstation running image
processing algorithms. Slides are scanned initially and cells of interest are separated from the background of
inflammatory cells, cellular debris or overlapping cell clusters. Image segmentation algorithms perform a separation
of the nuclei from the cytoplasm of the cells allowing the calculation of nuclear size, nucleus to cytoplasm ratio or
even definition of the texture of the observed object. None of the currently available systems, however, FocalPoint™
GS Imaging system (BD) or the ThinPrep™ Imaging system (Hologic), provides fully automated screening without
human intervention at some stage. The final decision still lies with the cytologist, resulting in the same subjectivity
problem as in manual screening. The MAVARIC trial [7] showed no improvement in sensitivity or specificity of
automated screening when compared to manual screening or in cost-effectiveness despite a 60%-80% increase in
productivity for automated screening.
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2.2 HPV testing
HPV testing trials have recently been conducted in order to evaluate their effectiveness for primary and secondary
screening as well as for proof-of-cure for safe and cost-effective lengthening of the cervical screening interval due to
high negative predictive values [8]. Many studies have shown that HPV testing has higher sensitivity (>95%) but
lower specificity (~ 84%) than cytology [9, 10]. HPV DNA tests, such as Hybrid Capture 2 (Qiagen), Cervista HPV
HR and Cervista HPV 16/18 (Hologic) and cobas HPV (Roche) assays, identify high-risk HPV oncogene expression,
while HPV E6/E7 mRNA based assays, such as APTIMA HPV assay (Gen Probe), identify the messenger RNA of
two HPV viral oncogenes, E6 and E7.

However, these tests are expensive, time-consuming and provide no

information on cervical cytopathology. Over the last decade, prophylactic HPV vaccines have been developed, but,
despite the introduction of these vaccines, there is still a need for regular cervical screening, as the vaccines do not
protect against all oncogenic HPV types. Additionally, some women may not benefit from the vaccines if there is a
pre-existing HPV infection or they do not receive the complete number of doses. After vaccination, women must
still have routine Pap tests which can detect abnormal cervical growth regardless of what HPV type causes it to
develop [11].

2.3 Histopathology
An abnormal Pap smear is followed by colposcopy, biopsy and histopathology. Microscopic evaluation by a pathologist
of a stained tissue section obtained from a biopsy is currently regarded as the “gold standard” in cancer diagnostics
and is called pathologic histology or histopathology.
After collection during colposcopy, the tissue is fixed and processed into a paraffin wax block. Tissue sections,
usually between 2 - 7 μm, are cut on a microtome and transferred to a slide for staining with Haematoxylin & Eosin
(H&E). The histological slide is then ready for examination under a light microscope by a trained pathologist. Figure
2 shows a H&E stained normal cervical tissue section showing stromal, basal / parabasal and intermediate /
superficial layers.

Based on histopathological characteristics of the tissue, grading assesses the degree of

malignancy or aggressiveness of the abnormal cells by comparing various parameters such as cellular anaplasia,
differentiation and mitotic activity with counterparts in normal cells and tissue. However, the grading characteristics
can be quite subjective and pre-malignancy may not be visually perceptible at all. The sensitivity and specificity of
colposcopy guided biopsy has been shown to be 75-90% and 97-99% respectively [12], but the subjective
interpretation of histologic classification is the main issue leading to poor inter-observer agreement [13 - 15].
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Current gold standard methods for detection of cervical cancer and pre-cancer are therefore limited and there is an
unmet clinical need for new objective screening or diagnostic tests.

3.

Raman spectroscopy

Vibrational spectroscopy analyses vibrations within a molecule and the spectrum of vibrational energies or
frequencies (in wavenumbers, cm−1) can be used to characterise a molecular structure. Every molecule has a unique
spectrum which allows identification of the molecular compound and its abundance in a sample [16]. The exact
energy required to excite a molecular vibration depends on the masses of the atoms involved in the vibration and the
strength of the chemical bonds between these atoms and may be influenced by molecular structure, molecular
interactions and the chemical microenvironment of the molecule.
Raman spectroscopy is an optical method based on inelastic light scattering. The sample is illuminated by monochromatic
laser light and interactions between the incident photons and molecules in the sample result in scattering of the light.
The coupling of the light generates vibrations within the material, which are again characteristic of the chemical
structure, and the energy of the scattered light is reduced by an amount equal to the energy of the vibrational energy.
Thus, the positions, relative intensities and shapes of the bands in a Raman spectrum carry detailed information about
the molecular composition of the sample.
Raman spectra of biomedical samples such as cells and tissues are a superposition of all the contributions from each
individual biochemical component such as DNA, RNA, proteins, lipids and carbohydrates. Thus, Raman
spectroscopy can provide a molecular diagnosis by providing a “biochemical fingerprint” of the complete genome,
proteome and metabolome of the cell or tissue [17]. This can be provided in a rapid, label free, non-destructive
manner, allowing additional analyses to be performed subsequently, such as staining, immunocytochemistry etc. In
recent years, Raman spectroscopy has been used in the detection of a variety of cancers, including breast, prostate,
oesophageal, colon, lung, oral and cervical cancer, and excellent sensitivity and specificity values have been reported
[18-20].
A typical Raman spectrum of cervical cells is shown in Figure 3, and a list of tentative spectral assignments is
provided in Table 1 [21]. The Raman spectrum was acquired using a HORIBA Jobin Yvon XploRATM system
(Villeneuve d’Ascq, France), which incorporates an Olympus microscope BX41 equipped with a x100 objective
(MPlanN, Olympus, NA = 0.9) and a 532 nm diode laser source. The power of the laser was set at 50%, resulting in
~8 mW at the objective. The confocal hole coupled to a slit of aperture 100 µm, was set at 100 m and a 1200
lines/mm grating was used. The system was pre-calibrated to the 520.7 cm-1 spectral line of silicon. The
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backscattered light was measured using an air-cooled CCD detector (Andor, 1024 x 256 pixels). Three spectra were
recorded from the cervical epithelial cell nucleus, each corresponding to the average of 3 accumulations of 10
seconds. Spectral pre-processing was performed using Matlab software (Mathworks) including smoothing (SavitzkyGolay, k=5; w=13), baseline correction (rubber band) and vector normalisation. The spectrum can be divided into
two regions, the fingerprint region, from 400–1800 cm−1, and the high wavenumber region, from 2500–3500 cm−1.
The high wavenumber region is dominated by C-H, N-H, O-H vibrations and can provide significant chemically
specific information, particularly on lipidic and protein structures. The fingerprint region similarly contains features
which can be associated with specific chemical moieties (e.g. C=C, C=O) but also contains features associated with
combinations of modes and more extensive macromolecular vibrations such as skeletal vibrations. As it is
considerably richer in information, it is often favoured for (multivariate) chemical analysis.

3.1 Raman spectroscopy for cytopathology
As shown in figure 1, a typical normal cervical smear contains epithelial cells, such as superficial cells, intermediate
cells, parabasal cells, as well as metaplastic cells, endocervical cells and endometrial cells, and non-epithelial cells,
such as white blood cells. Figure 4 shows an unstained cervical smear sample and the same sample after Pap
staining with the cells of interest indicated by arrows. Mean Raman spectra recorded from the unstained sample from
superficial cells, intermediate cells, parabasal cells and white blood cells are also shown. Raman spectra were
acquired as previously described for Figure 3. The spectra show considerable similarity as they are all measured
from the cell nucleus but some qualitative differences can also be found. The white blood cells show increased
contributions from nucleic acid bases around 800 cm-1 and 1580 cm-1.

Parabasal cells show increased

contributions from Amide III and phosphate stretching at 1240 cm-1 while superficial cells differ from intermediate
cells mainly due to increased contributions from guanine and C-H deformation in proteins and carbohydrates at 1340
cm-1.
Interestingly, the Raman spectra in figure 4 were recorded directly from Thinprep slides prepared according to
current cytopathology laboratory standard procedures apart from the Pap stain. The x, y co-ordinates of each
recorded cell were saved and, after Raman recording at 532 nm, the slides were Pap stained and each cell was revisited to verify whether it was a superficial, intermediate, parabasal or white blood cell. Spectroscopic substrates,
such as calcium fluoride, are commonly used for research purposes and although they reduce the presence of
confounding contributions of the substrate [22-24], they are considerably more expensive and thus not really a viable
choice for population screening applications such as cervical cancer screening. Although 785 nm is commonly used
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for biological applications of Raman spectroscopy, glass shows a strong background at this wavelength so to use
glass as a substrate for Raman spectroscopy, spectra must be recorded using shorter wavelengths such as 532 nm.

Initial vibrational spectroscopic studies (InfraRed spectroscopy) on cervical cytopathology performed in the early
1990’s recorded spectra from cell pellets rather than from individual cells [25-27] and a number of confounding factors
such as the presence of polymorphs, endocervical columnar cells, metaplastic cells, cervical mucus, blood and debris
were subsequently identified [28-33]. There have been relatively few studies using Raman spectroscopy for cervical
cytopathology, most likely because of issues with confounding factors.

A study by Rubina et al. [34] used Raman spectroscopy to distinguish between normal and cervical cancer cytology
samples. As the spectra of cervical cancer samples were dominated by blood features, cytology samples were treated
with red blood cell lysis buffer prior to Raman acquisition. However, the use of cell pellets rather than recording
Raman spectra from individual cells probably resulted in the relatively low classification accuracy of 80% due to
sample heterogeneity.

A recent study from our group [35] addressed many of the issues involved in recording Raman spectra from
ThinPrep cervical cytology samples. A new method based on pre-treatment of the slides with hydrogen peroxide to
clear blood residue contamination before Raman recording was shown to minimise variability within the data sets.
This resulted in the collection of highly reproducible data with clear discrimination between negative cytology and
CIN cytology. Importantly, all data was recorded on glass ThinPrep slides, commonly used in cytopathology
laboratories.

3.2 Raman spectroscopy for detection of HPV infection
HPV infection is accepted as one of the major risk factors associated with cervical cancer and detection of HPV
infection is being introduced as a routine screening methodolology. Incorporation of the virus into the cell induces
significant changes in the biochemistry which should also be identifiable using Raman spectroscopy.

Raman microspectroscopy has been used to distinguish between primary human keratinocytes (PHK), PHK cells
expressing the E7 gene of HPV16 (PHK E7) and cervical cancer cells expressing HPV16 (CaSki). The mean Raman
spectra showed variations in DNA and protein, consistent with HPV gene expression and neoplasia. Using principal

8

component analysis (PCA), Raman spectroscopy was shown to discriminate between PHK and CaSki cells with a
sensitivity of 93% and a specificity of 93% and between PHK and PHK E7 cells with a sensitivity of 93% and a
specificity of 80% [36].

Ostrowska et al. [37] used both infrared absorption and Raman spectroscopy to study a range of cervical cancer cell
lines. HPV negative (C33a) and low HPV copy number (SiHa with 1-2 copies) cell lines were shown to be
biochemically similar but significantly different from mid (HeLa) and high (CaSki) HPV copy number cervical
cancer cell lines. The main variations were observed for protein, nucleic acid and lipid and were confirmed by both
mean spectra and PCA analysis. Notably, the application of multivariate Partial Least Squares Regression analysis,
with HPV copy number as target, demonstrated that the dataset can be used to evaluate the degree of HPV infection,
based on the spectral profile of the cells.

A study by Vargis et al. [38] used both cell lines and cytology samples to investigate the potential of Raman microspectroscopy to detect the presence of HPV. Classification accuracies of 89-93% were achieved for discrimination
between a HPV negative normal human keratinocyte cell line (NHEK), a HPV negative cervical cancer cell line
(C33a) and HPV positive cervical cancer cell lines (HeLa and SiHa). A classification accuracy of 98.5% was
achieved for discrimination between HPV-positive and HPV-negative cytology samples.

3.3 Raman spectroscopy for histopathology
As shown in figure 2, a typical normal cervical tissue section contains different cell layers such as stromal, basal /
parabasal and intermediate / superficial layers. Figure 5 shows parallel H&E stained and unstained cervical tissue
sections and a four cluster Raman spectral map showing three distinct layers. The Raman map was recorded using a
HORIBA Jobin Yvon HR 800 (Villeneuve d’Ascq, France) Raman microscope equipped with a x100 objective
(MPlanN, Olympus, NA = 0.9) and a 785 nm laser source. Raman scattering was collected through a 100 μm
confocal hole onto a Synapse air-cooled CCD detector for the range of 400-1800 cm-1 using a 300 lines/mm
diffraction grating, yielding a dispersion of ~1.5cm-1 per CCD pixel. The instrument was calibrated using the 520.7
cm-1 peak of silicon. Raman spectral mapping was performed using 2 x 15 seconds acquisitions with a step size of
18μm. Spectral pre-processing was performed using Matlab software (Mathworks) including smoothing (SavitzkyGolay, k=5; w=13), baseline correction (rubber band) and vector normalisation. K Means Cluster Analysis was used
to analyse the spectral data set from the Raman map. The blue cluster represents the stroma, the red cluster the basal
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/ parabasal layer, the green cluster the intermediate / superficial layer and the black cluster the substrate. Mean
Raman spectra representing the different clusters are also shown in figure 5. The most distinctive Raman bands in
the blue spectrum can be assigned to collagen (853cm-1, 921cm-1, 938 cm-1and 1245 cm-1) a major component of the
connective tissue layer or stroma. The red spectrum shows distinctive bands due to DNA bases, adenine (722 cm-1),
thymine (755 cm-1) and cytosine (782 cm-1), and the green spectrum shows bands at 480cm-1, 849cm-1 and 938 cm-1
indicating the accumulation of glycogen in the intermediate / superficial layer.

Krishna et al. studied formalin fixed cervical tissues using both Raman and FTIR spectroscopy. Normal and
malignant tissues could be distinguished with differences in protein, lipids and nucleic acid peaks and stronger
Amide III assignments, suggesting disordered, helical secondary protein structure, in malignant conditions [39].
Formalin fixed paraffin preserved (FFPP) cervical tissue sections were also investigated by Lyng et al. [40]. The
underlying biochemical changes associated with cervical precancer and cancer were shown to be due to a reduction
in glycogen and an increase in nucleic acids. The loss of differentiation, together with increased proliferation, in precancer results in reduced levels of glycogen, as normal cervical cells accumulate glycogen as they mature. A Raman
mapping study using frozen tissue sections showed that Raman spectroscopy could distinguish normal cervical tissue
from invasive cervical cancer tissue based mainly on collagen bands and CH stretching bands [41].Tan et al. [42]
used Raman spectral mapping and hierarchical cluster analysis (HCA) to differentiate between normal squamous
epithelium and CIN2 in FFPP tissue sections and it was shown that the Raman spectra associated with the CIN2
lesion clustered predominantly with those of the basal epithelial cells of the normal squamous epithelium, suggesting
that the cells of these regions share common biochemical profiles. Spectral features responsible for their
differentiation were associated with the amide I and amide III bands.
More recently, FFPP tissue sections from cervical biopsies classified as NILM, LSIL or HSIL were analysed
by Raman spectral mapping [43]. Together with K-means cluster analysis (KMCA), Raman mapping was able to
differentiate the NILM cervical tissue into three layers including stroma, basal/parabasal and superficial layers,
characterised by spectral features of collagen, DNA bases and glycogen respectively. In the LSIL and HSIL samples,
KMCA clustered regions of the superficial layer with the basal layer. Using PCA, biochemical changes associated
with disease were also observed in normal areas of the abnormal samples, where morphological changes were not
apparent, providing a clear indication of the potential of Raman spectroscopy to identify biochemical changes
associated with the initial stages of the disease, rather than just the morphological changes associated with later stage
disease and current clinical diagnosis.
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3.4 Raman spectroscopy for in vivo applications
Mahadevan-Jansen et al [44, 45] first showed the potential of Raman spectroscopy for in vivo detection of cervical
cancer and pre-cancer and developed a fibre optic probe for in vivo measurements. Increases in phospholipids and
DNA, ~1330, 1454 and 1650 cm-1, were associated with progression to high-grade dysplasia [44, 45].
Improvements in the overall classification accuracy of Raman spectroscopy from 88% to 94% were achieved by
including information on menopausal status and menstrual cycle [46]. Similarly, consideration of previous disease
history and proximity to dysplastic lesions was found to result in disease classification accuracy of 97% [47]. Further
studies investigated the influence of race, ethnicity, body mass index, parity and socioeconomic status on Raman
spectra from patients with a normal cervix and concluded that only body mass index and parity resulted in
significant variations of spectral profiles [48]. Their influence on dysplasia and cancer has not been assessed,
however. The potential of high wavenumber (2800-3700 cm-1) Raman spectroscopy for in vivo detection of cervical
pre-cancer has been explored by Huang and co-workers [49, 50]. Significant differences in Raman bands of lipids at
2850 and 2885 cm-1, proteins at 2940 cm-1 and the broad Raman band of water at 3400 cm-1 were observed in normal
and dysplastic cervical tissue, with a sensitivity of 93.5% and specificity of 97.8% achieved for identification of
dysplasia [49]. Simultaneous fingerprint and high wavenumber Raman spectroscopy has been shown to outperform
fingerprint or high wavenumber Raman spectroscopy alone, resulting in a sensitivity of 85.0%, specificity of 81.7%,
and overall diagnostic accuracy of 82.6%. Raman spectral differences between normal and dysplastic cervical tissue
were observed at 854, 937, 1001, 1095, 1253, 1313, 1445, 1654, 2946, and 3400 cm-1, mainly related to proteins,
lipids, glycogen, nucleic acids and water content in tissue [50].

4.

Future perspectives

The potential of Raman spectroscopy as a truly label free, objective, automatable diagnostic technique has been well
demonstrated through numerous research studies of numerous pathologies, both in vivo and ex vivo. Disease
diagnostics have long relied on visual differences in tissue appearance, aided in modern histopathology and cytology
by optical stains and microscopic technologies. However, such approaches, based on changes in tissue and cell
morphology, often show the later stages of disease development, rather than the underlying biochemical changes
associated with disease onset or aetiology. Raman spectroscopy provides a signature, or fingerprint of the biological
sample, based on the biochemical constituents, and subtle changes to the composition associated with disease or
external insult can be identified with high sensitivity with the aid of multivariate statistical analysis. As an optical
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technology, it can be applied microscopically or endoscopically, for ex vivo or in vivo applications, the former
including cytopathology or histopathology. Signatures of viral infection can also be clearly identified indicating that
the technique could ultimately compete with costly viral screening programmes, notably with the same
instrumentation and an integrated screening protocol.

Table 2 lists the advantages and disadvantages of the current screening/diagnostic methods and Raman spectroscopy
for cervical cancer. In cytology, the Pap smear test, and in histology, histochemical staining are well established and
in essence considered “gold standards”. Any new disruptive technology such as spectropathology has an obvious
relative disadvantage in that translation will require not only acceptance by the clinical community, but large scale
and costly clinical trials. Ultimately, although both current cytological and histological methods require ex vivo
samples and are thus to some degree invasive, Raman based spectropathology could be performed in vivo in a
completely non invasive fashion. The principle advantage of spectroscopic based techniques is that, once
established, the technique is completely objective, based on disease and/or disease aetiology related changes in
biochemical signatures, rather than relying on expert interpretation of morphological changes. This should minimise
the risk of misdiagnosis due to variations in subjective human interpretation. Rapid analysis should also result in
rapid turn around to minimize patient anxiety. To date, much of the proof of concept research has been carried out on
high specification, laboratory apparatus, requiring expert users. However, given the increasing availability of lower
specification and cost, user friendly Raman instruments, this technology could readily translate to clinical
laboratories. Although the readout is a Raman spectrum, using pre-defined classification algorithms, a non-specialist
operator could receive an output such as a yes, no, or maybe (or Red, Orange Green) indicator for the presence of
cancer or pre-cancer.
However, despite the obvious potential, to date vibrational spectroscopic techniques have seen limited if any
translation into the clinical environment. A critical assessment of the challenges facing the translation of
spectroscopic methods to the clinical arena has recently been presented [51]. “Spectropathology for the Next
Generation: Quo Vadis?” summarises the discussion sessions of the SPEC 2014 conference, the 8th in the series of
bi-ennial flagship conferences in the field, which were led by members of the International Advisory Board.
Although the potential of the techniques has been well demonstrated in the research environment, and many of the
technical challenges associated with sample presentation, data acquisition, processing and analysis have been
addressed, it is clear that the lack of studies of the scale of clinical relevance is an obstacle to their credibility and
uptake. Widespread engagement of the medical community and commitment from instrument manufacturers as well
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as the resources required for large scale clinical trials may depend on the availability of such large scale studies. In
this context, the identification of strategic, achievable target applications is recommended.
Due to the high throughput of established screening programmes, cervical cytopathology is potentially such a
strategic target application. A key consideration is how the spectroscopic technique could fit into the current
workflow. Notably, the Pap smear protocol introduces cytological stains which can interfere with the Raman
acquisition, introducing substantial fluorescence background and/or photodegradation, depending on the wavelength
employed. With automated spectral acquisition, however, the implementation could be similar to the Thinprep
Imager (Hologic) or the Focal Point GS Imaging system (BD), which use image processing algorithms to
automatically review liquid based cytology Thinprep and SurePath slides. Raman spectroscopy is reagent free, so
costs should be favourable when compared to the imaging systems or to manual scoring where personnel costs could
be reduced. A recent study by our group [35] has shown that glass ThinPrep slides can be used for Raman spectral
recording in place of spectroscopic substrates, such as calcium fluoride substrates. These substrates reduce the
presence of confounding contributions of the substrate but they are considerably more expensive than the glass slides
used in the cytopathology laboratory.
Notably, the same data acquisition and screening protocol can be applied for identification of HPV infection, as the
technique is based on biochemical signatures, and thus, with appropriately trained spectral databases and data mining
protocols, the spectral profiling could provide an integrated analysis of health status and risk of developing HSIL or
cervical cancer, combining the advantages of the currently employed cytological and HPV screening standards, with
higher sensitivity, specificity and throughput.
Similar potential advantages of Raman spectroscopic approaches for histopathology can be identified, although it is
recognised that current mapping/imaging times of large areas of tissue followed by current pre- and post- data
processing protocols need to be improved [52]. Although significant progress has been made, there is much to be
done in terms of standardising procedures and protocols. The demands on the ability to rapidly scan large areas of
tissue probably currently favour the use of FTIR rather than Raman spectroscopy for such applications. In terms of
tissue processing protocols, there remains much debate, although consistency with current clinical practice probably
favours the use of FFPP tissue samples. Notably, analyses of archived tissue libraries may add much to
understanding disease progression and patient prognosis. It has been demonstrated that it is not necessary to remove
the paraffin to obtain usable spectral information [53]. Leaving the paraffin in place reduces scattering artefacts and
effects of further variable removal of aromatic solvent soluble components. However, it may be argued that greater
consistency of spectral information is achieved when sections are deparaffinised. Deparaffinising also allows post-
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staining of the sections, although it has been demonstrated that the efficiency of the deparaffinisation process can
depend on the tissue pathology [23].
In vivo applications are reliant on the further development of spectroscopic probes, which have already been
demonstrated for cervical applications [44-50]. Raman spectroscopy could be a potential candidate for an adjunct
tool for ‘screen and treat’ approaches for low resource countries. Patients are screened by visual inspection during
colposcopy and treated immediately by cryotherapy if required. Raman spectroscopy could be used to improve the
poor sensitivity of colposcopy in identifying cervical cancer and pre-cancerous lesions.
However, much work still remains before these techniques could be translated into standard clinical practice. Many
studies have used relatively small sample sizes and as such may be biased. Validation in large multi centre studies is
needed using real world cytopathology and histopathology samples from screening programmes and colposcopy
clinics. Large scale clinical trials are needed to obtain the large volumes of data necessary for the development of
robust classification algorithms.
If spectroscopy can be shown to be as good as, or better than, the gold standards in current use, then there is great
potential for these techniques to be used as an alternative or an adjunct to the current methods. The advantages
would be higher accuracy, higher throughput and reduced workload for the cytologist/pathologist and higher
accuracy and chance of earlier detection for the patient. It is important, however, to establish standard operating
procedures, through networks such as as the UK EPSRC Network CLIRSPEC (www.clirspec.org) and the EU COST
Action Raman4Clinics (http://www.cost.eu/domains_actions/bmbs/Actions/BM1401), to engage spectroscopic
instrument and medical device industries to optimise data collection efficiencies, as well as to actively engage the
medical and clinical communities to encourage uptake and translation of the technologies.
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Figure Legends
Figure 1

Pap stained negative Thinprep slide showing parabasal (black arrowheads), intermediate (solid

arrows) and superficial (dashed arrows) cells and white blood cells (red arrowheads)

20

Figure 2

H&E stained normal cervical tissue section showing the stromal (blue arrow), basal /

parabasal (red arrow), intermediate / superficial layers (green arrow)
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Figure 3

Raman spectrum of cervical cells showing fingerprint and high wavenumber regions

22

Figure 4

(I) Pap stained negative Thinprep slide showing parabasal (black arrowheads), intermediate

(solid arrows) and superficial (dashed arrows) cells and white blood cells (red arrowheads) and (II) mean Raman
spectra from parabasal (light blue), intermediate (blue) and superficial (red) cells and white blood cells (bottom)

23

Figure 5

(I) Unstained and (II) H&E stained normal cervical tissue showing stromal, basal, intermediate

/ superficial layers, (III) Raman spectral map showing stromal (blue), basal (red) and intermediate / superficial
(green) layers and (IV) mean Raman spectra from each representative layer
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Table 1 Tentative peak assignments [15] for Raman spectrum shown in Figure 3.
Wavenumber (cm−1)

Raman Peak Assignments

621

C-C twisting mode of Phenylalanine (proteins)

642

C-C twisting mode of Tyrosine and Phenylalanine

670

Thymine, Guanine (DNA/RNA)

720

C-N stretching in Adenine and lipids

750

symmetric breathing of Tryptophan (protein)

782

Uracil, Thymine, Cytosine (ring breathing modes in the DNA/RNA)

827

PO2 stretching in DNA, Tyrosine

854

Ring breathing in Tyrosine and Proline (proteins)

935

C-C stretching mode of Proline and Valine

1003

C-C aromatic ring stretching in Phenylalanine

1030

C-H bending mode in Phenylalanine, C-N stretching in proteins

1080

PO2 symmetric stretching (DNA/RNA)

1085

C-O stretching

1130

C-N stretching in proteins; C-O stretching in carbohydrates

1155

C-C and C-N stretching of proteins/lipids
C-H in plane bending mode of Tyrosine and Phenylalanine; Cytosine,

1175
Guanine
1208

C-C6H5 stretching mode in Tryptophan, Phenylalanine;
Amide III (C-N stretching, N-H bending, proteins), PO2 asymmetric stretching

1220–1280
(DNA/RNA)
1311

CH3/CH2 twisting mode of collagen and lipid

1340

Guanine (DNA/RNA), CH def. in proteins and carbohydrates

1430–1460

CH (CH2) bending mode in proteins and lipids
Amide II (N-H bending, C-N stretching, proteins); Adenine, Guanine

1485
(DNA/RNA)
1580

Adenine, Guanine (DNA/RNA); C=C bending mode of Phenylalanine

1615

C=C Phenylalanine, Tyrosine and Tryptophan

1620–1700

Amide I (C=O stretching, C-N stretching and N-H bending, proteins)

25

2890

CH2 symmetric stretching (lipids)

2940

CH2 and CH3 symmetric stretching (lipids)

2980

CH3 symmetric stretching (lipids)
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